Hemangioma Market Research Report - Forecast To 2030

Hemangioma Market information, by type (Capillary hemangioma, Cavernous hemangioma, Compound hemangioma, Lobular capillary hemangioma (pyogenic granuloma), and others), by diagnosis (Ultrasound, MRI, CT scan, and others), by Treatment (medical therapies, laser therapy, surgery) - Forecast to 2030

ID: MRFR/Pharma/2349-HCR | February 2023 | Region: Global | 68 Pages         

Market Synopsis of Hemangioma Market:


Market Scenario:


The Hemangioma Market is projected to reach USD 725.4 Million by 2030 at 4.3% CAGR during the forecast period 2022-2030


Hemangioma is the birthmark or benign tumors of infancy that occurs due to an abnormal collection of blood vessels. This occurs in 5-10% of infants worldwide. Increasing cases of hemangioma, increasing use of technology, and different treatment options are key drivers for the Hemangioma market. Increasing knowledge about the disorder and treatment, introduction of new drugs and therapies, and rapidly changing medical technology are major driving forces of the market. Increasing investment in R&D to develop more advanced product for the market is another major factor for the market.


Study objectives of Hemangioma Market:



  • To provide detailed analysis of the Hemangioma market structure with historical and forecast revenue for the next 7 years of the various segments and sub-segments of the market

  • To provide insights about the key drivers, restraints, opportunities and challenges that affecting the growth of the market

  • To provide analysis of the market with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.

  • To provide detail analysis of the market that segmented on the basis of type, by diagnosis, by treatment, and its sub-segments.

  • To provide detail analysis of global market mainly based on value chain analysis, Porter’s five forces, Price analysis, and Supply Chain analysis etc.

  • To provide detail country level analysis of the market with respect to the current market size and future prospective

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Hemangioma Market

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the Hemangioma market


FIGURE 1    GLOBAL HEMANGIOMA MARKET SHARE, BY DIAGNOSIS (%) HEMANGIOMA MARKET SHARE, BY DIAGNOSIS


Key Players:  



  • Akrimax Pharmaceuticals

  • LLC. (US)

  • AstraZeneca (UK)

  • Cutting Edge Laser Technologies (US)

  • Linline Medical Systems (France)

  • Novartis AG (Switzerland)

  • Pfizer Inc. (US)

  • Pierre Fabre (US

  • Quanta System S.p.A. (Italy)


Segments:      


Global Hemangioma Market has been segmented on the basis of type which Capillary hemangioma, Cavernous hemangioma (Cerebral cavernous malformations, Liver cavernous hemangioma, Eye cavernous hemangioma), Compound hemangioma, Lobular capillary hemangioma (pyogenic granuloma), and others. Cavernous hemangioma is further sub-segmented into cerebral cavernous malformations, liver cavernous hemangioma, and Eye cavernous hemangioma.


On the basis of diagnosis, it is segmented into Ultrasound, MRI, CT scan, and others.


On the basis of treatment, the market is segmented into medical therapy, laser therapy, surgery, and others. Medical therapy is further sub-segmented into systemic, intralesional and topical. Laser therapy is sub-segmented into Flash lamp pulsed dye laser, intralesional laser, carbon dioxide laser.


Research Methodology: Research Methodology of Hemangioma Market


 Sources: Directorate of Industries, Annual report, White paper, Company Presentation


Regional Analysis:         


Considering the global scenario of the market, due to continuous innovation and rapid adoption of new drugs and therapies, North America is holding largest market for Hemangioma. In North America region, US attributes largest market share. European market is second largest, and especially the growth rate is higher in west European countries. On the other hand, developing healthcare infrastructure, and increasing healthcare spending, the Asia-Pacific (APAC) is fastest growing market for Hemangioma and expected to grow significantly during the forecast period. Middle East and Africa (ME&A) is likely to have a limited growth in the market due to less awareness of treatment and products.


The report for Global Hemangioma Market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions Intended Audience



  • Hemangioma medicines and devices manufacturers

  • Hemangioma medicines and devices providers

  • Hospitals and clinics

  • Medical Research laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors



Report Scope:

Report Attribute/Metric Details
  Market Size   USD 725.4 Million
  CAGR   2022-2030:~4.3%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Type, Diagnosis, Treatment
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Akrimax Pharmaceuticals, LLC. (US), AstraZeneca (UK), Cutting Edge Laser Technologies (US), Linline Medical Systems (France), Novartis AG (Switzerland), Pfizer Inc. (US), Pierre Fabre (US) Quanta System S.p.A. (Italy)
  Key Market Opportunities

  • Continuous innovation and rapid adoption of new drugs and therapies
  • Developing healthcare infrastructure, and increasing healthcare spending in the Asia-Pacific (APAC)
  •   Key Market Drivers

  • Increasing investment in R&D to develop more advanced product
  • Rapidly changing medical technology


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The hemangioma market valuation would be USD 725.4 million by 2030.

    The hemangioma market CAGR would be 4.3% during the forecast period.

    The diagnosis types included in the hemangioma market are MRI, CT scan, Ultrasound, and others.

    The Americas would dominate the hemangioma market.

    The Asia Pacific region would record high hemangioma market CAGR.